While recent controversies over domestic costs of pharmaceuticals have placed the problem on the national stage, there has ultimately been a failure to produce substantive solutions. Through panels and interviews with healthcare experts across the public and private sectors, The Atlantic and Express Scripts examined whether market-based approaches will work to balance drug prices with critical research and development.